|
|
News Breaks | | | | March 13, 2013 | | 13:09 EDT |  | NAVB, CAH | FDA approves Navidea Lymphoseek injection for use in lymphatic mapping
Navidea Biopharmaceuticals (NAVB) announced U.S. Food and Drug Administration approval of Lymphoseek Injection, a novel product indicated for use in lymphatic mapping procedures to assist in the localization of lymph nodes draining a primary tumor in patients with breast cancer or melanoma. Lymphoseek will be sold and distributed in the U.S. on an exclusive basis by Cardinal Health (CAH). | |
|
News For NAVB;CAH From The Last 14 Days Check below for free stories on NAVB;CAH the last two weeks. |
|
|
| June 12, 2013 | | 10:33 EDT |  | CAH | Cardinal Health management to meet with Cleveland Research
Meeting to be held in Denver on June 14 hosted by Cleveland Research. | | | 09:03 EDT | | NAVB | Navidea's Lymphoseek shows positive meta-analysis results
Navidea announced results from a meta-analysis study of Lymphoseek (technetium Tc 99m tilmanocept) Injection, a novel, receptor-targeted, small-molecule radiopharmaceutical. The study compared Lymphoseek performance data from a pre-planned interim analysis of its Phase 3 clinical trial versus published data from the ACOSOG Z-0360 trial which was done using radiolabeled sulfur colloid. Results demonstrated that Lymphoseek identified sentinel lymph nodes in subjects with squamous cell carcinoma of the head or neck with a False Negative Rate of 2.56%, whereas sulfur colloid demonstrated an FNR of 10%. Lymphoseek identified SLNs with an overall accuracy of 99%, versus an overall accuracy of sulfur colloid of 97%. | | | June 11, 2013 | | 09:03 EDT | | NAVB | Navidea announces positive results from study of Lymphoseek Injection
 Subscribe for More Information | | | June 10, 2013 | | 16:19 EDT | | NAVB | Navidea announces results from two breast cancer studies
Subscribe for More Information | |
|
|
|
|
|
|
